Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4249 trials
Conditions Suicide, Mental Health Disorder, Anhedon...
Phase NA
Enrollment 78
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-29
Study Details Design, interventions, and primary outcomes

About This Study

Despite efforts to prevent suicide, US rates are climbing, and suicide is the second leading cause of death among youth. Digital tools, especially personal smartphones, are promising avenues to address these issues and can be used to provide a unique understanding of risk factors, including psychological distress, anhedonia and behavioral withdrawal, and sleep disturbance among high-risk individuals. This project aims to enhance the effectiveness of the delivery of preventative health care to youth at risk for suicide by developing a comprehensive digital platform that allows practitioners to integrate mobile sensing data and HIPAA-compliant client communication tools into their management of these young people.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Vira — Intensive outpatient DBT supported by the Vira platform. The Vira app is installed on the patient's smartphone. The app passively collects data from phone sensors (i.e., measures of physical activity, sleep patterns, mobility, and language patterns reflecting mood states and cognition) that are indicative of risk-relevant behavioral patterns and psychological states. It also prompts users to answer a daily check in question. Mobile sensing data are processed to provide an automated assessment of the user's functioning. Patients will be asked to use Vira for the duration of their intensive outpatient treatment. Patients' use of the Vira app is supported by practitioners, who can schedule just-in-time reminders (i.e., "nudges") to arrive in the user's phone at scheduled times to support their behavior change plan and DBT treatment. The Vira Platform therefore integrates mobile sensing, self-report assessment, and just-in-time nudges and notifications into the practitioner's workflow.
  • Behavioral: Treatment as Usual (TAU) — Intensive outpatient DBT + EARS app (passive data monitoring software)

Primary Outcomes

  • Columbia Suicide Severity Rating Scale (C-SSRS) (6 months)
  • Scale for Suicidal Ideation (SSI) (6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-08-14
Completion: 2026-12-31
Eligibility
Age: 13 Years and older
Sex: ALL
Volunteers: false
Enrollment: 78 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Ksana Health
Collaborators: Columbia University, National Institute of Mental Health (NIMH)
Principal Investigators:
  • Nick Allen, PhD (PRINCIPAL_INVESTIGATOR) - Ksana Health
Contact Information
Study Contact:
Randy Auerbach, PhD, ABPP
646-774-5745
rpa2009@cumc.columbia.edu
Randy Auerbach, PhD, ABPP
646-774-5745
rpa2009@cumc.columbia.edu
Columbia University
Interventions
  • Behavioral: Vira — Intensive outpatient DBT supported by the Vira platform. The Vira app is installed on the patient's smartphone. The app passively collects data from phone sensors (i.e., measures of physical activity, sleep patterns, mobility, and language patterns reflecting mood states and cognition) that are indicative of risk-relevant behavioral patterns and psychological states. It also prompts users to answer a daily check in question. Mobile sensing data are processed to provide an automated assessment of the user's functioning. Patients will be asked to use Vira for the duration of their intensive outpatient treatment. Patients' use of the Vira app is supported by practitioners, who can schedule just-in-time reminders (i.e., "nudges") to arrive in the user's phone at scheduled times to support their behavior change plan and DBT treatment. The Vira Platform therefore integrates mobile sensing, self-report assessment, and just-in-time nudges and notifications into the practitioner's workflow.
  • Behavioral: Treatment as Usual (TAU) — Intensive outpatient DBT + EARS app (passive data monitoring software)
Study Locations (1 sites)
Columbia University, New York, New York 10032 United States
Eligibility Criteria
Inclusion Criteria: * Written informed assent from adolescents ages 13-17 years old and permission from legal guardians, or consent from adolescents age 18 years old. * Receiving treatment at the Intensive Adolescent and Family DBT Pgogram * 13-18 years old * Owns a personal smartphone (Android or iPhone 7+) * Fluent in English Exclusion Criteria: * Adolescents who require a higher level of care (i.e., are not admitted to the Intensive Outpatient DBT program) * Adolescents who are receiving treatment at the Intensive Adolescent and Family DBT program and have already been assigned a clinician
Conditions Perinatal Mental Health
Phase NA
Enrollment 72
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-29
Study Details Design, interventions, and primary outcomes

About This Study

The objective of this study is to develop and pilot test a telehealth-based mental health screening and engagement program that supports parents as their infants transition home from the NICU. The program will use a stepped-care approach to screen parents for depression, anxiety, and PTSD; provide a brief behavioral intervention to those who screen as having at least a low risk of these conditions; and provide a warm hand-off to community mental health services for those at medium to high risk.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Health Services Research Masking/blinding: None

Interventions / Regimen

  • Behavioral: Behavioral Treatment — anticipatory guidance, brief behavioral intervention, or referral to community mental health provider

Primary Outcomes

  • Mental health self-efficacy scale (~2 weeks prior to discharge; 2 weeks post-discharge; 6 weeks post-discharge)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-04-22
Completion: 2026-04-30
Eligibility
Age: Not reported
Sex: ALL
Volunteers: false
Enrollment: 72 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Colorado, Denver
Collaborators: Oregon Health and Science University, National Institute of Mental Health (NIMH)
Contact Information
Study Contact:
Susanne Klawetter, PhD
303-724-1646
susanne.klawetter@cuanschutz.edu
Sunah S Hwang, MD, PhD, MPH/MSPH
720-848-0000
sunah.hwang@childrenscolorado.org
Susanne Klawetter, PhD
303-724-1646
susanne.klawetter@cuanschutz.edu
University of Colorado Hospital
Interventions
  • Behavioral: Behavioral Treatment — anticipatory guidance, brief behavioral intervention, or referral to community mental health provider
Study Locations (2 sites)
University of Colorado Hospital, Aurora, Colorado 80045 United States
Oregon Health & Science University, Portland, Oregon 97239 United States
Eligibility Criteria
Inclusion Criteria: * NICU parents: Participants will be parents of currently hospitalized preterm infants from either the OHSU NICU or the UCH NICU. We will include parents of live preterm infants who have been admitted in the NICU for at least 2 weeks. Parents must speak English or Spanish. Parents can be of any age. * NICU stakeholders: Participants will be stakeholders from either the OHSU NICU or the UCH NICU. Stakeholders will be social workers, mental health providers responsible for providing more intensive mental health support for NICU parents, nurses, neonatologists, and hospital administrators.
Conditions Mental Health Issue, Cognitive Symptom, ...
Phase Not Applicable
Enrollment 300
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-29
Study Details Design, interventions, and primary outcomes

About This Study

The PrimeCog study aims to describe the symptomatology and pathophysiology of stress-induced exhaustion disorder (SED) and major depressive disorder (MDD) compared to healthy controls (HC). The participants will be recruited at primary care centers, and samples of blood, saliva, and hair will be collected. Digital questionnaires covering psychosocial variables and screening instruments for the detection of depression, anxiety, etc., along with a digital cognitive test battery, will be performed at home. Subsequently, an MRI of the brain will be performed, and analysis of biomarkers for stress, inflammation, and neurodegeneration will be conducted. These procedures will be repeated after twelve and twenty-four months. The study will investigate differences in the biomarkers, neuroimaging findings, and cognitive abilities between patients with SED, MDD, and controls over time. Associations between the symptom severity of MDD/SED and psychosocial variables, cognition, MRI, and the biomarkers will also be examined. The aim is to provide new diagnostic tools for differentiation between MDD and SED and guide individualized treatment based on underlying pathophysiology and cognitive function. All necessary competences for conducting this extensive study are represented within the research group. The PrimeCog study is unique in its comprehensive design, addressing knowledge gaps, and directly comparing these diagnoses over time in primary care, where patients are typically treated.

Design

Study type: Observational Observational model: Case Control Time perspective: Prospective

Interventions / Regimen

  • Diagnostic Test: Cognitive Testing — Digital Cognitive Testing performed at home.

Primary Outcomes

  • Cognitive Test Results regarding attention and processing speed (At baseline, i.e. at diagnosis, at first study-specific follow-up (12 months from baseline), and at second study-specific follow-up (24 months from baseline))
  • Cognitive Test Results regarding attention and processing speed (At baseline, i.e. at diagnosis, at first study-specific follow-up (12 months from baseline), and at second study-specific follow-up (24 months from baseline))
  • Cognitive Test Results regarding attention and processing speed (At baseline, i.e. at diagnosis, at first study-specific follow-up (12 months from baseline), and at second study-specific follow-up (24 months from baseline))
  • Cognitive Test Results regarding attention and processing speed (At baseline, i.e. at diagnosis, at first study-specific follow-up (12 months from baseline), and at second study-specific follow-up (24 months from baseline))
  • Cognitive Test Results regarding memory (At baseline, i.e. at diagnosis, at first study-specific follow-up (12 months from baseline), and at second study-specific follow-up (24 months from baseline))
  • Cognitive Test Results regarding memory (At baseline, i.e. at diagnosis, at first study-specific follow-up (12 months from baseline), and at second study-specific follow-up (24 months from baseline))
  • Cognitive Test Results regarding executive function (At baseline, i.e. at diagnosis, at first study-specific follow-up (12 months from baseline), and at second study-specific follow-up (24 months from baseline))
  • Cognitive Test Results regarding executive function (At baseline, i.e. at diagnosis, at first study-specific follow-up (12 months from baseline), and at second study-specific follow-up (24 months from baseline))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-04-01
Completion: 2029-04-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 300 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Region Östergötland
Principal Investigators:
  • Hanna Israelsson Larsen, PhD (PRINCIPAL_INVESTIGATOR) - Region Ostergotland/Linkoping University
  • Anna Segernas, PhD (PRINCIPAL_INVESTIGATOR) - Region Ostergotland/Linkoping University
Contact Information
Study Contact:
Hanna Israelssion Larsen, PhD
+46738317008
hanna.israelsson.larsen@regionostergotland.se
Anna Segernäs, PhD
+46733641430
anna.segernas@liu.se
Hanna Israelsson Larsen, PhD
0738317008
hanna.israelsson.larsen@regionostergotland.se
Region Ostergotland, primary care centrum
Interventions
  • Diagnostic Test: Cognitive Testing — Digital Cognitive Testing performed at home.
Study Locations (1 sites)
Region Ostergotland, primary care centrum, Linköping, Östergötland County Sweden
Eligibility Criteria
Inclusion Criteria: 1. adults 18 to 65 years old; 2. fluent in Swedish; 3. corrected to normal vision and hearing; 4. (for cases), newly diagnosed with MDD or SED (i.e., received as new diagnosis at the visit to the physician) according to the diagnostic criteria from DSM-V (MDD) and the Swedish Board of Health and Welfare (SED) Exclusion Criteria: 1. already ongoing treatment for MDD/SED or previous diagnosis of MDD/SED within the last year; 2. history of serious mental illness (defined as mental illness that has required psychiatric in-patient care); 3. acute cerebrovascular event or severe head trauma in the last 6 months; 4. known cognitive impairment; 5. substance dependence, ongoing or past; 6. motor disability or impairment affecting interaction with the digital tests; 7. photosensitive epilepsy or -migraines. For the MRI subgroup, any contraindication to MRI is an exclusion criterion.
Conditions Depression, Alcohol Use Disorder
Phase PHASE1, PHASE2
Enrollment 34
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-29
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to investigate the effects of ketamine, in combination with standard inpatient addiction therapy, for adults with depression and alcohol use disorder. After screening and enrollment, participants will undergo baseline assessments of depression, measures of alcohol use and craving, as well as neurocognitive function. Participants will then be randomized to either ketamine (intervention) or midazolam (control). All participants will be admitted for standard inpatient addiction therapy while receiving ketamine or midazolam. Measures on safety, depression and alcohol use disorder will be repeatedly assessed during and after treatment. Final follow-up assessment is scheduled 6 months after baseline assessment.

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Drug: Ketamine Hydrochloride — Four single-doses, given two times per week for two weeks Dose: 0,8 mg/kg body weight Route of administration: intravenous infusions over 40 minutes
  • Drug: Midazolam Hydrochloride — Four single-doses, given two times per week for two weeks Dose: 0,02 mg/kg body weight Route of administration: intravenous infusions over 40 minutes

Primary Outcomes

  • Depression (Within 3 days after final treatment session)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2025-01-20
Completion: 2027-07-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 34 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University Hospital of North Norway
Collaborators: University of Exeter
Principal Investigators:
  • Ole K Grønli, Assoc Prof (STUDY_DIRECTOR) - University Hospital of North Norway
  • Andreas W Blomkvist, M.D. (PRINCIPAL_INVESTIGATOR) - University Hospital of North Norway
Contact Information
Study Contact:
Andreas W Blomkvist, M.D.
41694637
andreas.wahl.blomkvist@unn.no
Ole K Grønli, Assoc Prof
91713535
ole.k.gronli@unn.no
Andreas W Blomkvist, Senior consultant
+4741694637
andreas.wahl.blomkvist@unn.no
Department of Addiction, University Hospital of North Norway
Interventions
  • Drug: Ketamine Hydrochloride — Four single-doses, given two times per week for two weeks Dose: 0,8 mg/kg body weight Route of administration: intravenous infusions over 40 minutes
  • Drug: Midazolam Hydrochloride — Four single-doses, given two times per week for two weeks Dose: 0,02 mg/kg body weight Route of administration: intravenous infusions over 40 minutes
Study Locations (1 sites)
Department of Addiction, University Hospital of North Norway, Tromsø, Norway
Eligibility Criteria
Please contact the project team for a full and detailed list of inclusion/exclusion criteria Inclusion Criteria: * Currently abstinent from alcohol * At least moderate depression without psychotic features * Minimum Montgomery-Åsberg Depression Rating Scale (MADRS) of 20 * Alcohol dependence * Admitted for inpatient addiction therapy at University Hospital of North Norway Exclusion Criteria: * Intoxicated or in significant withdrawal from alcohol or drug use * Not able to give adequate informed consent * Current or past history of schizophrenia, schizophreniform disorder, paranoid delusional disorder, schizoaffective disorder * Current or historical diagnosis of schizophrenia in a first degree relative * Cardiovascular conditions: recent stroke (\< 1 year from informed consent), recent myocardial infarction (\< 1 year from informed consent), uncontrolled hypertension (\>150/100 mm Hg) or recent arrhythmia (\< 1 year from informed consent; clinically significant arrhythmia requiring treatment at hospital) * Liver (Child-Pughs Class C) or kidney (Creatinin clearance \< 30 mL/min) failure * Heart failure (the New York Heart Association Functional Classification (NYHA) class III or IV) * Chronic respiratory failure (requiring long-term oxygen therapy (LTOT) and/or Global Initiative for Chronic Obstructive Lung Disease system (GOLD) stage 3 or higher) * Previous anaphylactic reaction to ketamine or midazolam * Illegal use of ketamine the last 6 months * Pregnancy or breastfeeding * Current or suspected increased intracranial pressure
Conditions Depression
Phase NA
Enrollment 90
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-29
Study Details Design, interventions, and primary outcomes

About This Study

Depression is a disabling condition in terms of psychosocial alteration and also in terms of physical comorbidities. Depression doubles the risk of myocardial infarction compared with the general population, and this cardiovascular comorbidity leads to an increase in mortality in patients suffering from depression, even exceeding suicide-related mortality. It is therefore important to better understand the mechanisms linking depression and cardiovascular disease. Among the hypotheses that may account for the increased cardiovascular risk in patients with depression, lipid abnormalities are likely to play a crucial role. Thus, qualitative and functional abnormalities in HDL lipoproteins are an important line of research, insofar as these lipid abnormalities have been recognized as important atherogenic abnormalities in populations at high cardiovascular risk, which is the case of patients with depression. In this clinical, epidemiological and scientific context, a collaborative study undertaken by both the Department of Psychiatry of the Dijon Bourgogne University Hospital of and the INSERM LNC-UMR 1231 (PADYS) Laboratory of the UNIVERSITY OF BOURGOGNE FRANCHE-COMTE is an original translational research project, and the first study to perform a lipidomic analysis of HDL, coupled with a functional analysis of these lipoproteins in depression.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Parallel Primary purpose: Other Masking/blinding: None

Interventions / Regimen

  • Other: HDRS-17 depression scale — Measuring the severity of depression
  • Biological: Blood sampling — 3 tubes of 5 ml

Primary Outcomes

  • Measurement of cholesterol efflux by fluorescent method on THP-1 cell derived macrophages (At baseline)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2021-10-01
Completion: 2027-10
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 90 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Centre Hospitalier Universitaire Dijon
Contact Information
Study Contact:
Jean-Christophe CHAUVET-GELINIER
03 80 29 37 69
jean-christophe.chauvet-gelinier@chu-dijon.fr
Jean-Christophe CHAUVET-GELINIER
03 80 29 37 69
jean-christophe.chauvet-gelinier@chu-dijon.fr
Chu Dijon Bourgogne
Interventions
  • Other: HDRS-17 depression scale — Measuring the severity of depression
  • Biological: Blood sampling — 3 tubes of 5 ml
Study Locations (1 sites)
Chu Dijon Bourgogne, Dijon, 21000 France
Eligibility Criteria
Inclusion Criteria: * FOR PATIENTS WITH RECURRENT DEPRESSION : * Patient who has provided oral consent * Adult with moderate to severe depression according to DSM-5 criteria (Hamilton HDRS-17 score ≥ 18), with a number of depressive episodes ≥ 3 * PATIENTS PRESENTING WITH A FIRST DEPRESSIVE EPISODE * Patient who has provided oral consent * Adult with moderate to severe characterized depression according to DSM-5 criteria (Hamilton HDRS-17 scale score ≥ 18) presenting with a first depressive episode. * CONTROLS * Person who has provided oral consent * Adult who has never shown signs of depression Exclusion Criteria: * Person not affiliated with national health insurance * Person subject to a measure of legal protection (curatorship, guardianship) * Pregnant or breastfeeding women * Adult unable to express consent * Minors * Person with a metabolic syndrome (according to NCEP/ATP-III criteria: 3 of the following 5 criteria: Waist circumference ≥ 102 cm in males and ≥ 88cm in females, Triglycerides \> 1.50 g/L, HDL-Cholesterol \< 0.40 g/L in H, HDL-Cholesterol \< 0.50 g/L in F, Blood pressure ≥130/85mmHg, Fasting blood glucose ≥ 1.10 g/L), * Person with type 1 or type 2 diabetes, * Person with a mild depressive episode (HDRS-17\<18), * Person with concomitant antipsychotic treatment * Person with bipolar disorder, * Person with a moderate to severe alcohol use disorder according to DSM-5 criteria * Person with schizophrenia, * Person with a persistent delusional disorder, * Person with an autism spectrum disorder.
Conditions Rumination, Worry, Self-Criticism, Anxie...
Phase NA
Enrollment 36
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-29
Study Details Design, interventions, and primary outcomes

About This Study

This study is an open trial designed to examine individual changes that occur before, during, and after 6 modules of Emotion Regulation Therapy (ERT) delivered via telehealth for individuals in New York State who are experiencing elevated worry, rumination, or self-criticism.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Emotion Regulation Therapy via Telehealth — The initial stage of treatment focuses on psychoeducation about anxiety/depression, the impact that these cognitions/behaviors/emotions have on recent situations, and self-monitoring of worry/anxiety/depression. The sessions focus on the development of skills that help understand and regulate one's emotional experience (i.e., recognizing emotions when they are happening, identifying the meaning of a given emotion experience, soothing oneself in the context of negative emotional experiences). Following the development of these skills, sessions focus on the application of somatic awareness and emotion regulation skills while imagining emotionally evocative themes. The remaining session focuses on terminating therapy, relapse prevention, and future goals. An Internet-based online platform will be used to promote engagement with and increase accessibility to between-session skills practice and treatment-related activities (e.g., self-monitoring, session summaries, worksheets).

Primary Outcomes

  • Weekly Assessment of Change in Attentional Control (Weekly from Baseline (2 weeks) through Treatment (12-22 weeks) and Follow-Up (4 weeks))
  • Weekly Assessment of Change in Decentering (Weekly from Baseline (2 weeks) through Treatment (12-22 weeks) and Follow-Up (4 weeks))
  • Weekly Assessment of Change in Reappraisal (Weekly from Baseline (2 weeks) through Treatment (12-22 weeks) and Follow-Up (4 weeks))
  • Weekly Assessment of Change in Valued Living/Action (Baseline, 1st Treatment Session, Follow-Up (4 weeks))
  • Weekly Assessment of Change in Clarity of Approach-Avoidance Motivation (Baseline, 1st Treatment Session, Follow-Up (4 weeks))
  • Weekly Assessment of Change in Rumination (Weekly from Baseline (2 weeks) through Treatment (12-22 weeks) and Follow-Up (4 weeks))
  • Weekly Assessment of Change in Worry (Weekly from Baseline (2 weeks) through Treatment (12-22 weeks) and Follow-Up (4 weeks))
  • Weekly Assessment of Change in Self-Criticism (Weekly from Baseline (2 weeks) through Treatment (12-22 weeks) and Follow-Up (4 weeks))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-10-24
Completion: 2028-09-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 36 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Teachers College, Columbia University
Principal Investigators:
  • Douglas S Mennin (PRINCIPAL_INVESTIGATOR) - Professor of Clinical Psychology
Contact Information
Study Contact:
Douglas S Mennin
212.678.6609
mennin@tc.columbia.edu
Moises Hernandez
212.678.6609
emotionregulationtherapy@gmail.com
Douglas S Mennin, PhD
212-678-6609
mennin@tc.columbia.edu
Teachers College, Columbia University
Interventions
  • Behavioral: Emotion Regulation Therapy via Telehealth — The initial stage of treatment focuses on psychoeducation about anxiety/depression, the impact that these cognitions/behaviors/emotions have on recent situations, and self-monitoring of worry/anxiety/depression. The sessions focus on the development of skills that help understand and regulate one's emotional experience (i.e., recognizing emotions when they are happening, identifying the meaning of a given emotion experience, soothing oneself in the context of negative emotional experiences). Following the development of these skills, sessions focus on the application of somatic awareness and emotion regulation skills while imagining emotionally evocative themes. The remaining session focuses on terminating therapy, relapse prevention, and future goals. An Internet-based online platform will be used to promote engagement with and increase accessibility to between-session skills practice and treatment-related activities (e.g., self-monitoring, session summaries, worksheets).
Study Locations (1 sites)
Teachers College, Columbia University, New York, New York 10027 United States
Eligibility Criteria
Inclusion Criteria: * Between the ages of 18 and 65 * Fluent in English (and therefore able to provide consent) * Currently living in New York State * Access to at least one device with internet and video-conferencing capabilities * High self-reported worry, rumination, and/or self-criticism * Meet Diagnostic and Statistical Manual of Mental Disorders - Fifth Edition (DSM-5) criteria for at least one, current psychological disorder Exclusion Criteria: * Active suicidal ideation or intent * Substance dependence disorder, schizophrenia, bipolar-I disorder, or a primary DSM-5 diagnosis of borderline or narcissistic personality disorder * Currently in therapy or receiving any type of psychosocial treatment * Individuals taking psychotropic mediation that has not been stabilized for a period of at least 3 months * Current students at Teachers College, Columbia University
Conditions HIV, Depression, Cannabis Use Disorder, ...
Phase NA
Enrollment 120
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-29
Study Details Design, interventions, and primary outcomes

About This Study

This is a basic human experimental study utilizing 4 groups of individuals with and without HIV and complex morbidities of cannabis use disorder and major depression who will participate in 2 sessions of the Yale Pain Stress Task (YPST) and follow-up phase to assess drug use and mood symptoms.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Parallel Primary purpose: Basic Science Masking/blinding: None

Interventions / Regimen

  • Other: Yale Pain Stress Task (YPST) — Individuals in the experimental cohort will be scheduled for 2 experimental sessions 1-3 days apart. The YPST stress experiment includes a stress and no-stress session (order randomly assigned, counter-balanced across subjects), and involves multiple (up to 3) unpredictable number of consecutive 3-minute trials of ice-bath (stress) or warm-bath (no stress) forearm immersion (stress) with subjective, physiologic endocrine and immune assessments repeated at specified time points.

Primary Outcomes

  • Change in cortisol levels (day 1 and day 3)
  • Change in adrenocorticotropic hormone (ACTH) levels (day 1 and day 3)
  • Change in pain stress (day 1 and day 3)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-01-16
Completion: 2030-01-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Yale University
Collaborators: National Institute on Drug Abuse (NIDA)
Principal Investigators:
  • Rajita Sinha, Ph.D. (PRINCIPAL_INVESTIGATOR) - Yale University
Contact Information
Study Contact:
Rachel Hart, MA
203-737-4791
Rachel.hart@yale.edu
Interventions
  • Other: Yale Pain Stress Task (YPST) — Individuals in the experimental cohort will be scheduled for 2 experimental sessions 1-3 days apart. The YPST stress experiment includes a stress and no-stress session (order randomly assigned, counter-balanced across subjects), and involves multiple (up to 3) unpredictable number of consecutive 3-minute trials of ice-bath (stress) or warm-bath (no stress) forearm immersion (stress) with subjective, physiologic endocrine and immune assessments repeated at specified time points.
Study Locations (1 sites)
The Yale Stress Center, New Haven, Connecticut 06519 United States
Eligibility Criteria
Inclusion Criteria: * good health as verified by screening examination * Able to read English and complete study evaluations and provide informed written and verbal consent. Additional criteria PLWH * HIV-1 lab test positive * undetectable viral load * good ART adherence Additional criteria by group: PLWH +CM: * CB positive urine toxicology * meet DSM-5 criteria for CUD and MDD as assessed using SCID-I. HC * HIV-1 test negative * urine toxicology negative * no major medical and psychiatric diagnoses based on DSM-V. PLWH Only: * HIV-1 test positive * urine toxicology negative * no major medical and psychiatric diagnoses based on DSM-V. CM Only: * HIV-1 test negative * urine toxicology positive * meet DSM-5 criteria for CUD and MDD as assessed using SCID-I Exclusion Criteria: * meet primary, current moderate and severe criteria for other SUD including cocaine, alcohol, opiates, sedatives, nicotine * current use or past history of cocaine or opioid use disorder * history of any psychotic disorder * current diagnoses of bipolar disorder and PTSD * psychotic or otherwise severely psychiatrically disabled (i.e., suicidal, homicidal, current mania) * significant underlying medical conditions such as cerebral, renal, thyroid or cardiac pathology that would interfere with study participation * medications with known central effects on HPA axis and cytokines/immune function * women who are pregnant, nursing or those using hormonal birth control that affect HPA axis cortisol responses.
Conditions Bipolar Disorder (BD), Depression - Majo...
Phase NA
Enrollment 160
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-29
Study Details Design, interventions, and primary outcomes

About This Study

The aim of this clinical trial is to investigate the effects of a three-week virtual reality-based cognitive remediation training (VR-CRT) programme in combination with daily intake of a histone deacetylase inhibitor (HDACi) sodium butyrate on cognition in symptomatically stable patients with mood disorders (depression or bipolar disorder). The investigators hypothesize that the VR-based cognitive remediation training (VR-CRT) combined with HDACi butyrate vs. a VR-based control treatment combined with placebo will improve global cognition (primary outcome measure) over three weeks. Secondly, the investigators hypothesize that VR-CRT with placebo will improve cognition relative to the VR control treatment with placebo, although to a lesser extent than VR-CRT with HDACi butyrate. Thirdly, the investigators hypothesize that the HDACi butyrate with VR control treatment will not produce cognitive improvements relative to placebo with VR control treatment. Finally, the investigators hypothesize that the combined treatment (VR-CRT + HDACi butyrate) will enhance neuroplasticity (exploratory outcome) vs. VR control with placebo, as indicated by increase in hippocampal volume and/or memory-related activity shown with structural and functional MRI.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Behavioral: Virtual Reality-based cognitive remediation therapy (VR-CRT) — VR-CRT on 360° Meta Quest 2-software in which participants train cognitive abilities guided by a therapist. The platform includes three immersive scenarios: (1) a kitchen scenario focusing on planning and cooking a meal, (2) a supermarket scenario focusing on grocery shopping and (3) a restaurant scenario focusing on remembering names and personal information. The virtual reality training is supported by a psychoeducation program that focuses on application of learned cognitive strategies in daily life.
  • Behavioral: Virtual Reality-based control treatment (VR-CT) — VR-CT: The virtual reality control training involves completing different virtual reality games that are available through the Meta Quest games store. The chosen games involve no direct training of cognitive abilities such as planning skills og strategic learning, but merely involves simple reaction time and interaction with an entertaining environment that is meaningful to the participant and gives the impression of training cognitive skills.
  • Dietary Supplement: HDACi butyrate — Daily intake of sodium butyrate.
  • Dietary Supplement: Placebo — Daily intake of placebo.

Primary Outcomes

  • Cognitive composite measure (Baseline, week 4 (treatment completion. Primary outcome assessment time point) and week 8 (follow-up))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-11-14
Completion: 2028-07-01
Eligibility
Age: 40 Years and older
Sex: ALL
Volunteers: false
Enrollment: 160 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital
Principal Investigators:
  • Kamilla Woznica Miskowiak, DMSc, DPhil (PRINCIPAL_INVESTIGATOR) - Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital
  • Julian Macoveanu, PhD (STUDY_DIRECTOR) - Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital
Contact Information
Study Contact:
Bjørn Ole Barkholt Nordseth, Ph.D.-student
+4527134653
bjoern.ole.barkholt.nordseth@regionh.dk
Kamilla Woznica Miskowiak, DMSc, DPhil
+4522771617
kamilla.woznica.miskowiak@regionh.dk
Kamilla Woznica Miskowiak, DMSc, DPhil
+4522771617
kamilla.woznica.miskowiak@regionh.dk
Neurocognition and Emotion Across Disorders (NEAD Brain Centre, Copenhagen Affective Disorder Research Centre (CADIC), Psychiatric Centre Copenhagen, Frederiksberg Hospital
Interventions
  • Behavioral: Virtual Reality-based cognitive remediation therapy (VR-CRT) — VR-CRT on 360° Meta Quest 2-software in which participants train cognitive abilities guided by a therapist. The platform includes three immersive scenarios: (1) a kitchen scenario focusing on planning and cooking a meal, (2) a supermarket scenario focusing on grocery shopping and (3) a restaurant scenario focusing on remembering names and personal information. The virtual reality training is supported by a psychoeducation program that focuses on application of learned cognitive strategies in daily life.
  • Behavioral: Virtual Reality-based control treatment (VR-CT) — VR-CT: The virtual reality control training involves completing different virtual reality games that are available through the Meta Quest games store. The chosen games involve no direct training of cognitive abilities such as planning skills og strategic learning, but merely involves simple reaction time and interaction with an entertaining environment that is meaningful to the participant and gives the impression of training cognitive skills.
  • Dietary Supplement: HDACi butyrate — Daily intake of sodium butyrate.
  • Dietary Supplement: Placebo — Daily intake of placebo.
Study Locations (1 sites)
Neurocognition and Emotion Across Disorders (NEAD Brain Centre, Copenhagen Affective Disorder Research Centre (CADIC), Psychiatric Centre Copenhagen, Frederiksberg Hospital, Frederiksberg, Capital Region of Denmark 2000 Denmark
Eligibility Criteria
Inclusion Criteria: * Confirmed ICD-10 diagnosis of BD or recurrent UD in partial, or full remission (Hamilton Depression Rating Scale-17 items and Young Mania Rating Scale scores ≤14) * Subjective cognitive complaints (self-reported: COBRA ≥12) or objectively-verified cognitive impairment (measured using Screening for Cognitive Impairment in Psychiatry SCIP: total score or at least two subscores ≥ 0.5 SD below expected norms) * Fluency in Danish language Exclusion Criteria: * Diagnosis of schizophrenia * Neurological disorders (including dementia) * Dyslexia * Severe Physical illness * Kidney disease * Cardiovascular disease * Diabetes * Alcohol or substance abuse * Previous severe head trauma * History of epilepsy * Pregnancy or breastfeeding * BMI \>30 * Bodyweight \< 45kg * Daily use of benzodiazepines \> 22.5 mg. oxazepam or \> 7.5 mg. diazepam per day * Serum lithium levels \> 0.8 mmol/L * Received electroconvulsive therapy \< 2 months prior to participation * Hypertension (\>140 systolic or \> 90 diastolic mm Hg)
Conditions Glaucoma, Open-Angle Glaucoma, Ocular Hy...
Phase PHASE4
Enrollment 20
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-29
Study Details Design, interventions, and primary outcomes

About This Study

The objective of this study is to evaluate whether reduction in topical medication with the injection of a sustained release capsule (Durysta) leads to a reduction in ocular surface inflammation, indicated by levels of caspase-1, an inflammatory biomarker.

Design

Study type: Interventional Phases: Phase4 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Durysta, Bimatoprost Intracameral Implant 10 µg — Participants in this arm will receive a one-time injection of Durysta (intracameral bimatoprost 10mcg). Participants will be followed by a total of 3 months.

Primary Outcomes

  • Change in Caspase-1 mRNA Expression Following Durysta Injection (Baseline, post-injection 1 month, post-injection 3 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2026-02-09
Completion: 2028-01-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 20 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Miami
Collaborators: AbbVie
Principal Investigators:
  • Swarup S Swaminathan, MD (PRINCIPAL_INVESTIGATOR) - University of Miami
Contact Information
Study Contact:
Javier Paredes, BA, MBA
305-326-6387
jxp2537@med.miami.edu
Monica Arango, BA
305-326-6351
mrarango@med.miami.edu
Javier Paredes, BA, MBA
305-326-6387
jxp2537@med.miami.edu
Bascom Palmer Eye Institute
Interventions
  • Drug: Durysta, Bimatoprost Intracameral Implant 10 µg — Participants in this arm will receive a one-time injection of Durysta (intracameral bimatoprost 10mcg). Participants will be followed by a total of 3 months.
Study Locations (1 sites)
Bascom Palmer Eye Institute, Miami, Florida 33134 United States
Eligibility Criteria
Inclusion Criteria: * Eye with open-angle glaucoma or suspected of open-angle glaucoma * Pseudophakic in eye of interest with Shafer grading ≥3 * ≤ 3 daily applications of topical glaucoma medications for ≥6 months (of which one is a nightly preserved PGA) * Good adherence to medication regimen - screening questions to be asked of potential subject: * In the last month, what percentage of the time would you estimate missing the application of drops? (Must be ≤20%) * When was the last administration? (Last dose must have been within last 24 hours) * Presence of punctate epithelial erosions in the cornea (NEI scale \> 3) Exclusion Criteria: * Retinal disease (e.g., wet age-related macular degeneration, proliferative diabetic retinopathy, central retinal vein occlusion) * Use of topical or systemic immunosuppressor or immunomodulator drug (e.g., steroids, cyclosporine, lifitegrast, or antihistamines) * Use of preservative-free hypotensive medications * Any clinical contraindications to receiving intracameral bimatoprost implantation * History of recurrent conjunctivitis (e.g., allergic or atopic conjunctivitis) * History of partial or full corneal transplant * History of ophthalmic surgery (intraocular or tarsus-involving oculoplastic procedures) within last 6 months * History of subconjunctival glaucoma surgery (i.e., trabeculectomy, aqueous shunt, Xen implant) within last 6 months
Conditions Glaucoma, Open-Angle, Ocular Hypertensio...
Phase PHASE3
Enrollment 168
Locations 9 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-29
Study Details Design, interventions, and primary outcomes

About This Study

This is a randomized, double-blind, two-treatment, single-period, parallel design, multiple dose at multiple clinical trial sites designed to demonstrate bioequivalence with clinical endpoint in subjects with chronic open-angle glaucoma or ocular hypertension in both eyes. Test Product - Bimatoprost ophthalmic solution, 0.01% of Amneal EU, Limited Reference Product - LUMIGAN® (bimatoprost ophthalmic solution) 0.01% of Allergan, Inc.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Drug: Test - Bimatoprost 0.01% Ophthalmic Solution — Subjects in one arm will receive one drop of the test drug in both the eyes every evening at approximately 10:00 pm ± 1 hour for 42 days.
  • Drug: Reference - LUMIGAN® (Bimatoprost 0.01% Ophthalmic Solution) — Subjects in the other arm will receive one drop of the reference drug in both the eyes every evening at approximately 10:00 pm for 42 days.

Primary Outcomes

  • Mean difference in the intraocular pressure (IOP) of both eyes between the two treatment groups. (Day 14 and 42 at 00.00 hours, 04.00 hours, and 08.00 hours.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2022-06-29
Completion: 2022-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 168 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Amneal Pharmaceuticals, LLC
Collaborators: CBCC Global Research
Contact Information
Study Contact:
Ilesh Changela, MBBS; MD
+91-79-67778300
ilesh@amnealindia.com
David Wirta, MD
949-554-8763
Eye Research Foundation Inc.
Jason Bacharach, MD
North Bay Eye Associates, Inc.
Interventions
  • Drug: Test - Bimatoprost 0.01% Ophthalmic Solution — Subjects in one arm will receive one drop of the test drug in both the eyes every evening at approximately 10:00 pm ± 1 hour for 42 days.
  • Drug: Reference - LUMIGAN® (Bimatoprost 0.01% Ophthalmic Solution) — Subjects in the other arm will receive one drop of the reference drug in both the eyes every evening at approximately 10:00 pm for 42 days.
Study Locations (9 sites)
Eye Research Foundation Inc., Newport Beach, California 92663 United States
North Bay Eye Associates, Inc., Petaluma, California 94954 United States
Volusia Eye Associates, New Smyrna Beach, Florida 32169 United States
Clayton Eye Clinical Research, LLC, Morrow, Georgia 30260 United States
Coastal Research Associates, LLC, Roswell, Georgia 30076 United States
Toyos Clinic, Nashville, Tennessee 37215 United States
Keystone Research, Austin, Texas 78731 United States
Houston Eye Associates, North Loop, Houston, Texas 77008 United States
Cheyenne Eye Clinic & Surgery Center, Cheyenne, Wyoming 82001 United States
Eligibility Criteria
Inclusion Criteria: * Subjects willing and able to provide voluntary informed consent and to follow protocol requirements. * Male or females aged ≥18 years. * Subjects having body mass index (BMI) ≥18.50 kg/m2. * Subjects with chronic open-angle glaucoma or ocular hypertension in both eyes. * Subjects requiring treatment of both eyes and able to discontinue the use of all ocular hypotensive medication(s) or switch ocular hypotensive medications and undergo appropriate washout period. * Adequate washout period prior to baseline of any ocular hypotensive medications as per the table below (to minimize potential risk to subjects due to intraocular pressure (IOP) elevations during the washout period, the Investigator may choose to substitute a parasympathomimetic or carbonic anhydrase inhibitor in place of a sympathomimetic, alpha-agonist, beta-adrenergic blocking agent, or prostaglandin; however, all the subjects must have discontinued their ocular hypotensive medications for the minimum washout period. * Baseline (Day 0/hour 0) IOP ≥22 mm Hg and \<35 mm Hg in each eye, * Subjects' IOP is likely to be controlled with monotherapy as per the Investigator's discretion. * Baseline best corrected visual acuity equivalent to Snellen acuity of 20/100 or better in each eye, using a logarithmic visual acuity chart for testing at 10 feet (3 meters). * Women of childbearing potential (defined as women physiologically capable of becoming pregnant unless they are using an effective method of contraception during the dosing of the study drug) practicing any of the following acceptable methods of contraception: 1. Oral or parenteral (injection, patch, or implant) hormonal contraception which has been continuously used for at least 1 month prior to first dose of study medication 2. Intrauterine device (IUD) or intrauterine system (IUS) 3. Double barrier method of contraception (condom and occlusive cap or condom and spermicidal agent) 4. Male sterilization (at least 6 months prior to screening, should be the sole male partner for that subject) 5. Female sterilization (surgical bilateral oophorectomy) or tubal ligation at least 6 weeks prior to study participation 6. Total abstinence; partial abstinence is not acceptable * No history of addiction to any recreational drug or drug dependence or alcohol addiction. Exclusion Criteria: * Female who are pregnant, lactating or planning a pregnancy. * Contraindication or known hypersensitivity to Bimatoprost, related class of drugs, or any of the excipients of formulation. * Current or past history of severe hepatic or renal impairment. * Current or history within 2 months prior to baseline of any other significant ocular disease, e.g., corneal edema, uveitis, ocular infection, or ocular trauma in either eye (Note: stable myopia, strabismus, and cataracts as per the Investigator's discretion will be allowed provided that the other inclusion/exclusion criteria are met). * Current corneal abnormalities that would prevent accurate IOP readings with Goldmann applanation tonometer. * Functionally significant visual field loss in the Investigators' opinion. * Subject with corneal grafts. * Subject has contraindication to pupil dilation * Use at any time prior to baseline of an intraocular corticosteroid implant * Use of contact lens within 1 week prior to baseline * Use within 2 weeks prior to baseline of 1) a topical ophthalmic corticosteroid or 2) a topical corticosteroid * Use within 1 month prior to baseline of 1) a systemic corticosteroid or 2) high dose salicylate therapy defined as 325 mg/day and taken on 3 consecutive days. * Use within 6 months prior to baseline of intravitreal or subtenon injection of an ophthalmic corticosteroid * Underwent within 6 months prior to baseline any other intraocular surgery (e.g., cataract surgery). * Underwent within 12 months prior to baseline any refractive surgery, filtering surgery, or laser surgery for IOP reduction (e.g., laser trabeculoplasty). * Amblyopia - only one sighted eye. * Subjects with a history of IOP previously uncontrolled on bimatoprost monotherapy * Significant ocular surface findings (e.g., hyperemia or irritation, mild or greater) in either eye found on gross macroscopic or slit lamp examination * Severe retinal disease or other severe ocular pathology, such as glaucomatous damage with a cup/disk ratio greater than 0.8 (not including physiological cupping in the Investigators' opinion) or split fixation * Chronic use of any systemic medication that may affect IOP with less than 3 months stable dosing regimen (i.e., sympathomimetic agents, beta-adrenergic blocking agents, alpha-agonists, alpha-adrenergic blocking agents, calcium channel blockers, angiotensin-converting enzyme inhibitors, etc.) * Central Corneal thickness (CCT) \<450 microns or \>650 microns * Known history or presence of any uncontrolled systemic disease (e.g., cardiovascular disease, hypertension, diabetes mellitus, hepatic impairment, etc.) * History of recurrent ocular seasonal allergies within the past 2 years * Any other medical condition or serious intercurrent illness that, in the Investigator's opinion, may make it undesirable for the subject to participate in the study and would limit adherence to the study requirements * Participation in any clinical study within 90 days before the first dose of the study drug * Subjects with documented history of positive serology for Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) or Human Immunodeficiency Virus (HIV) infection * Subjects with positive urine pregnancy test * Subjects with confirmed novel coronavirus infection (COVID-19).
Conditions Preeclampsia, Preterm Birth, Pregnancy C...
Phase Not Applicable
Enrollment 7845
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-29
Study Details Design, interventions, and primary outcomes

About This Study

The Biobank includes data and biological specimens of women from three original studies: 1) First-trimester Prediction of Preeclampsia (PREDICTION Study, NCT02189148), 2) Pre-Eclampsia And growth Retardation, an evaluative Longitudinal study (PEARL Study, NCT02379832), 3) Effect of Low Dose Aspirin on Birthweight in Twins: The GAP Trial (NCT02280031) and 4)PREDICTION2: Prediction of Preeclampsia and other Pregnancy Complications Following Combined Iterative Screening.

Design

Study type: Observational Observational model: Other Time perspective: Prospective

Interventions / Regimen

  • Other: Observational — All women of the biobank have provided: 1. blood samples (plasma, serum and Buffy-coat) 2. urine samples 3. demographic and clinical data (maternal age, BMI, smoking status, obstetrical and medical history) 4. mean arterial blood pressure 5. ultrasound examination (datation of pregnancy at recruitment, uterine arteries doppler, placental volume, nuchal translucency in the majority of the cases) 6. access to medical record (for pregnancy/delivery outcomes, newborn birthweight, gestational age at delivery)

Primary Outcomes

  • early onset preeclampsia (diagnosed between 20 and 34 weeks of gestation)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2015-04
Completion: 2028-04
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: true
Enrollment: 7845 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: CHU de Quebec-Universite Laval
Principal Investigators:
  • Emmanuel Bujold, MD, MSc (PRINCIPAL_INVESTIGATOR) - CHU de Quebec
Contact Information
Study Contact:
Emmanuel Bujold, MD, MSc
418-525-4444
emmanuel.bujold@crchudequebec.ulaval.ca
Sylvie Tapp, MSc
418-525-4444
sylvie.tapp@crchudequebec.ulaval.ca
Emmanuel Bujold, MD, MSc
418-525-4444
emmanuel.bujold@crchudequebec.ulaval.ca
CHU de Quebec
Interventions
  • Other: Observational — All women of the biobank have provided: 1. blood samples (plasma, serum and Buffy-coat) 2. urine samples 3. demographic and clinical data (maternal age, BMI, smoking status, obstetrical and medical history) 4. mean arterial blood pressure 5. ultrasound examination (datation of pregnancy at recruitment, uterine arteries doppler, placental volume, nuchal translucency in the majority of the cases) 6. access to medical record (for pregnancy/delivery outcomes, newborn birthweight, gestational age at delivery)
Study Locations (1 sites)
CHU de Quebec, Québec, G1V 4G2 Canada
Eligibility Criteria
Inclusion Criteria: * (specific to each study) Exclusion Criteria: * pregnant women \<18 years old at recruitment * negative fetal heart at recruitment * women not able to provide an informed consent to the study
Conditions Fetal Growth Restriction (FGR), Preeclam...
Phase Not Applicable
Enrollment 12084
Locations 6 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-29
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this prospective cohort study is to examine how different parameters of assisted reproductive technologies (ART) are associated with the perinatal outcome in individuals with singleton or multiple gestations. The main questions it aims to answer are: Are ART pregnancies associated with a higher risk of: * Small for gestational age neonates? * Fetal growth restriction, either early- or late-onset? * Development of preeclampsia? * Stillbirth (intrauterine fetal death after 22 weeks not due to known anomalies)? * Are certain ART parameters-such as the type of fertilization (e.g., IVF vs. ICSI), embryo stage at transfer, use of fresh vs. frozen embryos, or ovarian stimulation protocols-more strongly associated with adverse outcomes? Are ART pregnancies associated with placental and umbilical cord abnormalities, including: * Placenta previa? * Vasa previa? * Single umbilical artery? * Velamentous or marginal cord insertion? Researchers will compare outcomes between pregnancies conceived through ART and those conceived spontaneously. Participants will: * Be individuals aged 18 or older undergoing routine first-trimester ultrasound between 11 and 14 weeks of gestation * Provide detailed medical, obstetric, and ART-related information * Undergo routine prenatal assessments, including ultrasound evaluations of fetal growth, Doppler studies, and placental characteristics * Have perinatal outcomes such as gestational age at birth, mode of delivery, birthweight, and complications systematically recorded Statistical models will be used to adjust for confounding factors such as maternal age, BMI, parity, and smoking. The aim is to better understand how ART and specific ART parameters may influence maternal and neonatal health and to improve counseling and clinical care for people using fertility treatments.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Small for gestational age neonates (At delivery/birth)
  • Development of preeclampsia (From the 20th gestational week and up to 8 weeks after the delivery/birth)
  • Fetal growth restriction (From the 22nd gestational week and up to the delivery/birth)
  • Stillbirth (From the 24th gestational week and up to the delivery/birth)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-10-01
Completion: 2028-12
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: true
Enrollment: 12084 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Aristotle University Of Thessaloniki
Collaborators: Hospital Universitario de Torrejón, Madrid, Universidad Francisco de Vitoria, University Hospital, Pleven, Bulgaria, Hospital Universitario Virgen de la Arrixaca, Hospital Universitario de Canarias
Contact Information
Study Contact:
Themistoklis Dagklis
+302313312120
dagklis@auth.gr
Antonios Siargkas
Petya Chaveeva
+359 64 884 100
chaveevapetya@gmail.com
University Hospital of Pleven
Interventions
N/A
Study Locations (6 sites)
University Hospital of Pleven, Pleven, 5800 Bulgaria
Aristotle University of Thessaloniki, Thessaloniki, Central Macedonia 54124 Greece
Complejo Hospitalario Universitario de Canarias, Santa Cruz de Tenerife, Canary Islands 38320 Spain
Universidad Francisco de Vitoria, Madrid, 28223 Spain
Hospital Universitario de Torrejón, Madrid, 28850 Spain
Hospital Clínico Universitario "virgen de la Arrixaca", Murcia, 30120 Spain
Eligibility Criteria
Inclusion Criteria * Singleton or multiple pregnancies * Live fetus between 11 weeks plus 0 days and 13 weeks plus 6 days of gestation Exclusion Criteria * Known genetic anomalies diagnosed before or after birth * Major fetal defects diagnosed before or after birth, such as acrania, holoprosencephaly, megacystis, exomphalos, congenital heart defects